Bio-Technology General's BioLon
This article was originally published in The Gray Sheet
Executive Summary
U.S. marketing of the viscoelastic ophthalmic product, which is indicated as a surgical aid for cataract extraction, intraocular lens implantation and anterior segment surgery, begins Nov. 9. BTG's distributor, Akorn, enters agreements with Allergan and Allegiance to provide "over 200" sales reps to market the device, a premarket approval application for which was approved in July. BTG attributes the delay of the launch to the need to finalize labeling and ramp up production at its Rehovot, Israel, manufacturing facility